SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-452324"
 

Search: onr:"swepub:oai:DiVA.org:uu-452324" > Elevated soluble am...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Johannesson, MalinBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-452324
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-452324URI
  • https://doi.org/10.1016/j.mcn.2021.103641DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147032197URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Down syndrome (DS) is caused by trisomy of chromosome 21, which leads to a propensity to develop amyloid beta (A beta) brain pathology in early adulthood followed later by cognitive and behavioral deterioration. Characterization of the A beta pathology is important to better understand the clinical deterioration of DS individuals and to identify interventive strategies. Brain samples from people with DS and Alzheimer's disease (AD), as well as nondemented controls (NDC), were analyzed with respect to different A beta species. Immunohistochemical staining using antibodies towards A beta was also performed. Elevated levels of soluble A beta protofibrils and insoluble A beta x-40 and A beta x-42 in formic acid brain extracts, and elevated immunohistochemical staining of A beta deposits were demonstrated with the antibody BAN2401 (lecanemab) in DS and AD compared with NDC. These data and the promising data in a large phase 2 CE clinical trial with lecanemab suggest that lecanemab may have the potential to preserve cognitive capacity in DS. Lecanemab is currently in a phase 3 CE clinical trial.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sahlin, CharlotteUppsala universitet,Geriatrik,BioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.(Swepub:uu)chste168 (author)
  • Söderberg, LindaBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)
  • Basun, HansUppsala universitet,Geriatrik,BioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.(Swepub:uu)habas169 (author)
  • Fälting, JohannaBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)
  • Möller, ChristerBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)
  • Zachrisson, OlofBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)
  • Sunnemark, DanKarolinska Institutet (author)
  • Svensson, AnneOffspring Biosci, Biovat Pk,Forsgatan 20 J, SE-15136 Södertälje, Sweden. (author)
  • Odergren, TomasBioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden. (author)
  • Lannfelt, LarsUppsala universitet,Geriatrik,BioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.;Uppsala Univ, Dept Publ Hlth Geriatr, SE-75122 Uppsala, Sweden.(Swepub:uu)lalan021 (author)
  • BioArctic AB, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.Geriatrik (creator_code:org_t)

Related titles

  • In:Molecular and Cellular Neuroscience: Elsevier1141044-74311095-9327

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view